Atrial Fibrillation Data Linkage Non-Interventional Study
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
12,556actual
Sites
1
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-21 | actual | When the study began enrolling |
| Primary completion | 2025-10-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-23 | actual | The whole study's end, after follow-up |
| First posted | 2023-04-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atrial Fibrillation
Primary outcomes
what the primary-completion date above is the date OFEvent Rate of Stroke/Systemic embolism (SE)
measured Up to 12 months after AF diagnosis or after the start date of relevant atrial fibrillation(AF) treatment
Event Rate of Major bleeding
measured Up to 12 months after the AF diagnosis or after the start date of relevant AF treatment
All-Cause Mortality Rates
measured Up to 12 months after the AF diagnosis or after the start date of relevant AF treatment
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed